Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.62 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.62 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.62 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577971 | 0.95 | OPRM1 (0.67) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL29578349 | 0.95 | OPRM1 (0.67) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL29578343 | 0.95 | OPRM1 (0.67) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL29577215 | 0.95 | OPRM1 (0.67) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL30276261 | 0.95 | ACE (0.65) | — | |
| SCHEMBL30287988 | 0.95 | OPRM1 (0.61) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL29577668 | 0.94 | ERAP1 (0.68) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL29577129 | 0.94 | ERAP1 (0.68) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL30010303 | 0.94 | ERAP1 (0.68) | OPRM1OPRD1ERAP1ERAP2LNPEP | |
| SCHEMBL30288009 | 0.94 | OPRM1 (0.62) | OPRM1OPRD1ERAP1ERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166967-B1 | SYNTHETIC SOMATOSTATIN RECEPTOR LIGANDS | TEL HASHOMER MEDICAL RES INFRASTRUCTURE & SERVICES LTD (IL) | 2023-03-08 | — | — | EP | claimed |
| CN-117122707-A | combination therapy | 意大利国际先进加速器应用有限公司 | 2023-11-28 | — | — | CN | disclosed |